IP Library Granted Patent US 11,241,461
Granted Patent B2
US 11,241,461 · App. 16/116,223 · Granted Feb 8, 2022

Treating cancer using a blautia strain

Inventors: Brian Goodman (Jamaica Plain, MA); Peter Sandy (Revere, MA); Jacqueline Papkoff (San Francisco, CA); Humphrey Gardner (Marblehead, MA); Holly Ponichtera (Cambridge, MA)
Assignee: Evelo Biosciences, Inc.
A61K35/74A61K35/742A61K38/19A61K38/193A61K38/217A61K39/395A61K45/06A61P35/00C12N1/20C12N1/205C12R2001/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,241,461
App. No.
16/116,223
Granted
Feb 8, 2022
Kind
B2
Abstract

Provided herein are methods and compositions related to Blautia Strain A useful as therapeutic agents.

Claims (15)

1. A method of inducing an anti-tumor immune response in a subject comprising orally administering to the subject an effective amount of a bacterial composition comprising Blautia Strain A (ATCC Deposit Number PTA-125134) wherein the subject has a tumor.

2. The method of claim 1 , wherein the tumor is a renal cell carcinoma, bladder cancer, prostate cancer, lung cancer, colon cancer, colorectal cancer, melanoma, breast cancer, pancreatic cancer or hepatocellular carcinoma tumor.

3. The method of claim 1 , wherein at least 50% of the bacteria in the bacterial composition are Blautia Strain A.

4. The method of claim 1 , wherein substantially all at least 99% of the bacteria in the bacterial composition are Blautia Strain A.

5. The method of claim 1 , wherein the bacterial composition comprises at least 1×10 6 colony forming units (CFUs) of Blautia Strain A.

6. The method of claim 1 , wherein the bacterial composition further comprises a pharmaceutically acceptable carrier.

7. The method of claim 1 , wherein the bacterial composition is formulated as a capsule or a tablet.

8. The method of claim 7 , wherein the capsule or tablet comprises an enteric coating.

9. The method of claim 8 , wherein at least 99% of the bacteria in the bacterial composition are Blautia Strain A.

10. The method of claim 9 , wherein the bacterial composition comprises at least 2×10 8 organisms of Blautia Strain A.

11. The method of claim 1 , wherein the bacterial composition comprises live bacteria, attenuated bacteria, or killed bacteria.

12. The method of claim 1 , wherein the method further comprises administering to the subject a second cancer therapy.

13. The method of claim 12 , wherein the second cancer therapy comprises the administration of a chemotherapy agent to the subject.

14. The method of claim 12 , wherein the second cancer therapy comprises administering an antibiotic to the subject.

15. The method of claim 1 , wherein the method further comprises administering a prebiotic to the subject.

Assignments (2)
SECURITY INTEREST Recorded Jul 14, 2023
From: EVELO BIOSCIENCES, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 064274/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2019
From: GOODMAN, BRIAN; SANDY, PETER; PAPKOFF, JACQUELINE; GARDNER, HUMPHREY; PONICHTERA, HOLLY
To: EVELO BIOSCIENCES, INC.
Reel/Frame 049515/0967 →
Continuity (4)
Provisional Application 62696429 · Jul 11, 2018
Provisional Application 62573406 · Oct 17, 2017
Provisional Application 62551554 · Aug 29, 2017
Related Publication 20190240267A1 · Aug 8, 2019